Social News
Written by: Yang Qian
2021-02-04 03:05
The last update date: 2021-02-04 03:05
British pharmaceutical company GlaxoSmithKline PLC (GSK, GSK.LN) announced on Wednesday that it has reached a 150 million euro ($180.7 million) cooperation with multinational biotechnology company CureVac NV to jointly develop a new variant of the new crown virus. A first-generation mRNA vaccine, with the goal of obtaining a license for launch in 2022
GlaxoSmithKline stated that it will start to develop the next-generation mRNA COVID-19 vaccine on the basis of CureVac’s first-generation COVID-19 vaccine candidate CVnCoV, and it is possible to develop a multivalent vaccine against multiple new virus variants.
According to the agreement, GlaxoSmithKline will be the holder of the marketing authorization for next-generation vaccines (except Switzerland), and will have the exclusive rights to develop, produce and commercialize in countries other than Germany, Austria and Switzerland.
The company will pay an advance payment of 75 million euros and an interim payment of 75 million euros.
The new generation vaccine can be used to protect people who have not been vaccinated before, or as an enhanced vaccine when the immunity of the first generation vaccine is reduced due to the evolution of the virus.
CureVac's first-generation new crown vaccine candidate CVnCoV is currently undergoing phase 2b and phase 3 clinical trials in Europe and Latin America. Interim data is expected to be obtained early this year. The vaccine can be stored under cold chain conditions at 2-8°C.
GlaxoSmithKline will also help CureVac produce up to 100 million doses of the first-generation new crown vaccine candidate CVnCoV in 2021.
New crown pneumonia丨British study: Extending the interval between 2 doses of AstraZeneca vaccine is more effective
New crown pneumonia丨The British Minister said the movie ``The War of the Century'' provided inspiration for formulating a vaccine plan
New crown vaccine | Kexing failed to submit the third phase of clinical report
New crown pneumonia丨British media: Monoclonal antibody therapy fails to effectively combat variant viruses
01News
New crown pneumonia new crown vaccine
